Plus Therapeutics, Inc.(PSTV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PSTV Plus Therapeutics, Inc.

Pre-Mkt 02-27 08:25:22 EST

0.3243

+0.0231

+7.67%

盘前0.3116

-0.0127-3.92%

08:25 EST

High0.3286	Low0.3000	Vol7.05M
Open0.3100	D1 Closing0.3012	Amplitude9.50%
Mkt Cap57.85M	Tradable Cap57.85M	Total Shares178.37M
T/O2.20M	T/O Rate3.95%	Tradable Shares178.37M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PSTV","market":"US","secType":"STK","nameCN":"Plus Therapeutics, Inc.","latestPrice":0.3243,"timestamp":1772139600000,"preClose":0.3012,"halted":0,"volume":7048996,"hourTrading":{"tag":"盘前","latestPrice":0.3116,"preClose":0.3243,"latestTime":"08:25 EST","volume":36453,"amount":11658.526045499999,"timestamp":1772198703480,"change":-0.0127,"changeRate":-0.039161,"amplitude":0.040703},"delay":0,"changeRate":0.0766932270916333,"floatShares":178371232,"shares":178371232,"eps":-0.455966,"marketStatus":"Pre-Mkt","change":0.0231,"latestTime":"02-27 08:25:22 EST","open":0.31,"high":0.3286,"low":0.3,"amount":2197136.66724008,"amplitude":0.094954,"askPrice":0.325,"askSize":2000,"bidPrice":0.3116,"bidSize":2164,"shortable":3,"etf":0,"ttmEps":-0.455966,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772202600000},"marketStatusCode":1,"adr":0,"listingDate":1134968400000,"exchange":"NASDAQ","adjPreClose":0.3243,"preHourTrading":{"tag":"盘前","latestPrice":0.3116,"preClose":0.3243,"latestTime":"08:25 EST","volume":36453,"amount":11658.526045499999,"timestamp":1772198703480,"change":-0.0127,"changeRate":-0.039161,"amplitude":0.040703},"postHourTrading":{"tag":"盘后","latestPrice":0.32,"preClose":0.3243,"latestTime":"19:55 EST","volume":50453,"amount":16008.9009,"timestamp":1772153751587,"change":-0.0043,"changeRate":-0.013259,"amplitude":0.050262},"volumeRatio":1.177572918083777},"requestUrl":"/m/hq/s/PSTV/tweets","defaultTab":"tweets","newsList":[{"id":"2614026006","title":"Lake Street Sticks to Their Buy Rating for Plus Therapeutics (PSTV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614026006","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614026006?lang=en_us&edition=fundamental","pubTime":"2026-02-26 23:48","pubTimestamp":1772120895,"startTime":"0","endTime":"0","summary":"In a report released today, Chad Messer from Lake Street maintained a Buy rating on Plus Therapeutics, with a price target of $2.00. Messer covers ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lake-street-sticks-to-their-buy-rating-for-plus-therapeutics-pstv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lake-street-sticks-to-their-buy-rating-for-plus-therapeutics-pstv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSTV"],"gpt_icon":0},{"id":"2614842690","title":"Plus announces new Category III CPT code for CED used with Reyobiq","url":"https://stock-news.laohu8.com/highlight/detail?id=2614842690","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614842690?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:39","pubTimestamp":1772023189,"startTime":"0","endTime":"0","summary":"Plus Therapeutics (PSTV) announced the American Medical Association’s, AMA, CPT, Current Procedural Terminology, Editorial Panel approved a new Cat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/plus-announces-new-category-iii-cpt-code-for-ced-used-with-reyobiq-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/plus-announces-new-category-iii-cpt-code-for-ced-used-with-reyobiq-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["III","BK4585","BK4215","BK4139","BK4134","CPT","PSTV","BK4588"],"gpt_icon":0},{"id":"2614849980","title":"Plus Therapeutics Inc: Are on Track to Complete Enrollment in Phase 2 Recurrent Glioblastoma Trial in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2614849980","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614849980?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:35","pubTimestamp":1772022901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL1BB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PSTV"],"gpt_icon":0},{"id":"2614084991","title":"Plus Therapeutics Announces New Category Iii Cpt Code for Convection-Enhanced Delivery Used With Reyobiq™","url":"https://stock-news.laohu8.com/highlight/detail?id=2614084991","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614084991?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:35","pubTimestamp":1772022901,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL1BB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PSTV"],"gpt_icon":0},{"id":"2614084961","title":"Plus Therapeutics Inc - New Cpt Code Effective January 1, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2614084961","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614084961?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:35","pubTimestamp":1772022901,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL1BB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PSTV"],"gpt_icon":0},{"id":"2614084530","title":"Plus Therapeutics Announces New Category III CPT Code for REYOBIQ Convection-Enhanced Delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=2614084530","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614084530?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:30","pubTimestamp":1772022622,"startTime":"0","endTime":"0","summary":"Plus Therapeutics Inc. said the American Medical Association’s CPT Editorial Panel approved a new Category III CPT code to track utilization of convection-enhanced delivery used to administer REYOBIQ for recurrent glioblastoma and pediatric brain cancer. The approved code is X566T, covering stereotactic placement of brain infusion catheter for delivery of therapeutic agents, including computerized stereotactic planning and burr hole. The company said the code will be published July 1, 2026, and will become effective for reporting on Jan. 1, 2027. Plus Therapeutics also said it expects to complete enrollment in its Phase 2 recurrent glioblastoma trial in 2026, followed by an end-of-Phase 2 meeting, and continues to expect first patient enrollment in its Phase 1 pediatric brain cancer trial in 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDLb7S3X6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","PSTV","BK4112","SG9999014005.SGD","SG9999014013.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","BK4588","BK4139","IE00BKPKM429.USD","LU2210150020.SGD","BK4585","LU2095319765.USD","SG9999014021.USD","NDAQ"],"gpt_icon":0},{"id":"2611193839","title":"Plus Therapeutics Approves 2025 Executive Compensation and Bonuses","url":"https://stock-news.laohu8.com/highlight/detail?id=2611193839","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611193839?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:10","pubTimestamp":1771017028,"startTime":"0","endTime":"0","summary":"Plus Therapeutics Inc. has announced updated compensation details for its executive team for the fiscal year ended December 31, 2025. The Compensation Committee approved discretionary cash bonuses for the company’s Named Executive Officers. President and Chief Executive Officer Marc H. Hedrick, M.D., will receive a total compensation package of $5,566,732 for 2025, which includes a base salary of $585,000, option awards valued at $3,531,841, restricted stock awards of $1,100,647, a non-equity incentive plan payout of $305,663, and other compensation totaling $43,581. The updated figures reflect the most recent decisions regarding executive remuneration for the year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDLQQr2f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSTV"],"gpt_icon":0},{"id":"2609306396","title":"Plus Therapeutics (PSTV) Gets a Buy from Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2609306396","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609306396?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:55","pubTimestamp":1770299716,"startTime":"0","endTime":"0","summary":"In a report released on February 3, Chad Messer from Lake Street initiated coverage with a Buy rating on Plus Therapeutics and a price target of $2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/plus-therapeutics-pstv-gets-a-buy-from-lake-street-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/plus-therapeutics-pstv-gets-a-buy-from-lake-street-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSTV","BK4139"],"gpt_icon":0},{"id":"2608874567","title":"Plus Therapeutics initiated with a Buy at Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2608874567","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608874567?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:40","pubTimestamp":1770126032,"startTime":"0","endTime":"0","summary":"Lake Street analyst Chad Messer initiated coverage of Plus Therapeutics (PSTV) with a Buy rating and $2 price target Plus recently relaunched CNSid...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/plus-therapeutics-initiated-with-a-buy-at-lake-street-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/plus-therapeutics-initiated-with-a-buy-at-lake-street-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","PSTV","BK4539","BK4139"],"gpt_icon":0},{"id":"2605406524","title":"Maxim Group Sticks to Their Buy Rating for Plus Therapeutics (PSTV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605406524","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605406524?lang=en_us&edition=fundamental","pubTime":"2026-01-23 22:36","pubTimestamp":1769178988,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Jason McCarthy maintained a Buy rating on Plus Therapeutics yesterday and set a price target of $1.50. According to TipRanks, M...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-plus-therapeutics-pstv-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-plus-therapeutics-pstv-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSTV"],"gpt_icon":0},{"id":"2605996794","title":"Plus Therapeutics announces anticipated milestones for FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2605996794","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605996794?lang=en_us&edition=fundamental","pubTime":"2026-01-22 20:50","pubTimestamp":1769086220,"startTime":"0","endTime":"0","summary":"Plus Therapeutics (PSTV) provided a business update and highlights REYOBIQ clinical progress and CNSide US commercialization. “Our 2 key goals in 2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/plus-therapeutics-announces-anticipated-milestones-for-fy26-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/plus-therapeutics-announces-anticipated-milestones-for-fy26-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","LENZ","BK4139","PSTV"],"gpt_icon":0},{"id":"2605293496","title":"Plus Therapeutics Inc - Reyobiq Phase 2 Trial Data Expected in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2605293496","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605293496?lang=en_us&edition=fundamental","pubTime":"2026-01-22 20:45","pubTimestamp":1769085900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nTUA6NT2P9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSTV","BK4139"],"gpt_icon":0},{"id":"2605443507","title":"BRIEF-Plus Therapeutics To Provide Business Update On Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2605443507","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605443507?lang=en_us&edition=fundamental","pubTime":"2026-01-22 06:02","pubTimestamp":1769032964,"startTime":"0","endTime":"0","summary":"BRIEF-Plus Therapeutics To Provide Business Update On ThursdayJan 21 (Reuters) - Plus Therapeutics Inc PSTV.O:PLUS THERAPEUTICS TO PROVIDE BUSINESS UPDATE AND HOST CONFERENCE CALL ON THURSDAY, JANUARY","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nTUA1BV0CX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSTV"],"gpt_icon":0},{"id":"2605435301","title":"Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2605435301","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605435301?lang=en_us&edition=fundamental","pubTime":"2026-01-22 05:15","pubTimestamp":1769030100,"startTime":"0","endTime":"0","summary":"HOUSTON, Jan.  21, 2026  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/21/3223245/0/en/Plus-Therapeutics-to-Provide-Business-Update-and-Host-Conference-Call-on-Thursday-January-22-2026-at-9-00-A-M-ET.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","PSTV","CNS","BK4181","ET","HST","LENZ","BK4139","BK4539","BK4144","BK4135","BK4218","BK4581","BK4561","BK4007","BK4588","BK4590"],"gpt_icon":0},{"id":"2604947680","title":"Benzinga Bulls And Bears: TSMC, Rocket Lab, J.B. Hunt — And Space Stocks Soar","url":"https://stock-news.laohu8.com/highlight/detail?id=2604947680","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604947680?lang=en_us&edition=fundamental","pubTime":"2026-01-17 21:21","pubTimestamp":1768656060,"startTime":"0","endTime":"0","summary":"Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/17/Bulls-and-Bears-1.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/17/Bulls-and-Bears-1.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/market-summary/26/01/49983763/benzinga-bulls-and-bears-tsmc-rocket-lab-j-b-hunt-and-space-stocks-soar","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/26/01/49983763/benzinga-bulls-and-bears-tsmc-rocket-lab-j-b-hunt-and-space-stocks-soar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["TQQQ","LU2041044095.USD","LU2089283258.USD","LU2471134796.USD","BK4585","LU1732799900.SGD","LU1868836757.USD","BK4127","BK4543","MS","LU2211815571.USD","LU0329931173.USD","LU1282649067.USD","IE00B3M56506.USD","LU0742534661.SGD","LU1712237335.SGD","BK4551","BK4082","LU1868837565.USD","LU0348723411.USD","LU0143863784.USD","LU0106831901.USD","LU0572939691.SGD","LU1989764748.USD","LU1720051017.SGD","IE00BFXG1179.USD","IE00B19Z3581.USD","BK4505","LU2491050071.SGD","LU0175139822.USD","LU0950373646.USD","LU2294711713.HKD","LU2237443465.HKD","LU0531971165.HKD","LU0359201885.HKD","BK4504","BK4023","IE0034235188.USD","LU0965509101.SGD","BK4022","LU1934455863.HKD","IE00BHPRN162.USD","BK4602","IE00BQXX3F31.USD","LU1803068979.SGD","SGXZ51526630.SGD","BK4581","LU2237443895.HKD","IE00BKPKM429.USD","LU0882574139.USD","LU0082616367.USD","LU1852331112.SGD","LU2360106780.USD","BK4089","LU0320765646.SGD","LU0106261372.USD","LU0109392836.USD","LU1023057109.AUD","BK4564","IE0004086264.USD","LU0323591593.USD","BK4588","LU0353189763.USD","QLD","LU0124676726.USD","TSM","LU1732800096.USD","LU1868837300.USD","LU1211504680.USD","LU0823421333.USD","SG9999004220.SGD","LU2237438978.USD","LU1989764664.SGD","LU2237443978.SGD","LU0345770993.USD","IE00BZ199S13.USD","LU2247934214.USD","QQQE","LU1868836591.USD","LU2087625088.SGD","LU2471134523.USD","BK4187","LU0572940350.SGD","LU0965509010.AUD","BK4534","LU0225283273.USD","LU2458330169.SGD","LU0488056044.USD","BK4587","BK4139","LU0048573561.USD","LU0096364046.USD","LU1868837722.USD","LU2092937221.SGD","BK4520","LU0289960550.SGD","LU1162221912.USD","BK4550","IE00BYQQ9H92.USD","LU0094547139.USD","BK4562","LU2237443622.USD","LU0098860793.USD","LU1244550221.USD","IE00BD6J9T35.USD","LU2023250504.SGD","LU0353189680.USD","SGXZ99366536.SGD","BK4077","USJW.SI","LU0158827781.USD","LU2106854487.HKD","LU2471134952.CNY","LU1868836914.USD","LU0158827948.USD","LU0234570918.USD","LU0878004406.USD","LU0882747503.HKD","LU1548497426.USD","LU1989772840.SGD","LU2271345857.HKD","LU1804176565.USD","NVIW.SI","QQQM","LU1244550577.SGD","RKLB","BK4116","LU1668664300.SGD","FLY","LU2125154778.USD","BK4527","LU2357305700.SGD","LU0316494557.USD","LU0861579265.USD","LU0329931090.USD","BK4141","BK4554","IE00BQXX3C00.GBP","LU0359202008.SGD","BK4528","LU0557290698.USD","LU0345770308.USD","LU0359201612.USD","LU1868838027.USD","LU0264606111.USD","BK4516","LU0251131958.USD","LU1974910355.USD","BK4552","LU2111349929.HKD","BK4097","BK4609","AI","LU2471134879.HKD","LU0795875086.SGD","LU1989772923.USD","JBHT","LU0965509283.SGD","LU2750360641.GBP","LU0314104364.USD","LU1791710400.SGD","LU1282649810.SGD","IE00BFXG0V08.USD","QID","LU0823431647.USD","LU2491049909.HKD","LU0198837287.USD","LU0823431563.USD","LU2249611893.SGD","TSYW.SI","03145","QQQJ","LU0541501648.USD","LU2023251221.USD","NQmain","LU0541502299.USD","IE00BZ1G4Q59.USD","LU0823414478.USD","LU1623119135.USD","LU2458330243.SGD","BK4232","LU2298321311.HKD","LU2663582299.SGD","LU1363072403.SGD","QYLD","LU0965508806.USD","LU0878005551.USD","LU1316542783.SGD","USAW.SI","SG9999000418.SGD","IE0009354923.USD","LU2125154935.USD","LU0061475181.USD","LU0267386448.USD","LU1917777945.USD","IE0004091025.USD","BK4532","IE00BKVL7J92.USD","LU1934455194.USD","LU0889565833.HKD","BK4612","LU0912757837.SGD","LU2028103732.USD","LU2491050154.USD","LU0689626769.HKD","LU2265009873.SGD","LU1791807156.HKD","LU1074936037.SGD","LU2211814178.USD","BK4526","BK4605","LU2054465674.USD","LU0795875169.SGD","LU1791710582.SGD","LU0971096721.USD","LU2357125470.USD","BK4533","PSTV","LU1508157978.USD","PSQ","SQQQ","IE00BSNM7G36.USD","BK4548","LU2347655156.SGD","LU2360032135.SGD","LU1868837136.USD","GS","LU1894683264.USD","BK4503","LU0823421416.USD","BK4591","LU0792757196.USD","IE00B5TLWC47.USD","LU1244550494.USD","LU1267930813.SGD","GPIQ","LU2133065610.SGD","LU0823414551.USD","LU1934455277.USD","LU1037948897.HKD","LU2860962120.EUR","LU1720051108.HKD","QQQY","MNQmain","LU0384037296.USD","LU2506951792.HKD","BK4512","LU2250418816.HKD","IE00B19Z3B42.SGD","IE00BQXX3D17.EUR","LU0719512351.SGD","IE0004445239.USD","LU0642271901.SGD","LU2750360997.AUD","SPCE","SGXZ81514606.USD","LU0056508442.USD","LU2237443382.USD","LU2089284900.SGD","LU0889566641.SGD","LU1037948541.HKD","LU0143863198.USD","LU0251142724.SGD","LU0528227936.USD","LU2063271972.USD","LU2543165471.USD","IE0002270589.USD","LU1894683348.USD","QYLG","LU2237443549.SGD","LU0238689110.USD",".IXIC","LU2360108059.USD","LU0006306889.USD"],"gpt_icon":1},{"id":"2604933919","title":"BRIEF-Plus Therapeutics Inc - On Jan 13, Co Enters Underwriting Agreement With Lake Street Capital Markets, Llc - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2604933919","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604933919?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:09","pubTimestamp":1768597785,"startTime":"0","endTime":"0","summary":"BRIEF-Plus Therapeutics Inc - On Jan 13, Co Enters Underwriting Agreement With Lake Street Capital Markets, Llc - SEC FilingJan 16  - SEC Filing:PLUS THERAPEUTICS INC - ON JAN 13, CO ENTERS UNDERWRITING AGREEMENT WITH LAKE STREET CAPITAL MARKETS, LLC - SEC FILINGPLUS THERAPEUTICS INC - TO ISSUE 39,473,684 SHARES AND WARRANTS AT $0.38 EACH - SEC FILINGPLUS THERAPEUTICS INC - NET PROCEEDS FROM OFFERING ABOUT $13.3 MILLION - SEC FILINGSource text: [ID:n0001193125-26-015346]Further company coverage: PSTV.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nFWN3YH1V4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSTV"],"gpt_icon":0},{"id":"2604791967","title":"Plus Therapeutics Inc - to Issue 39,473,684 Shares and Warrants at $0.38 Each - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2604791967","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604791967?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:08","pubTimestamp":1768597699,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nFWN3YH1V4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PSTV"],"gpt_icon":0},{"id":"2603641984","title":"Plus Therapeutics Prices Upsized $15 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2603641984","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603641984?lang=en_us&edition=fundamental","pubTime":"2026-01-15 03:49","pubTimestamp":1768420176,"startTime":"0","endTime":"0","summary":"Plus Therapeutics (PSTV) said Wednesday it priced an upsized underwritten public offering of about 39.5 million units at $0.38 each, expected to raise approximately $15 million in gross proceeds.Each ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4539","PSTV","BK4139","LENZ"],"gpt_icon":0},{"id":"2603164526","title":"Crude Oil Gains Over 1%; US Retail Sales Rise 0.6% In November","url":"https://stock-news.laohu8.com/highlight/detail?id=2603164526","media":"Benzinga","labels":["economic","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603164526?lang=en_us&edition=fundamental","pubTime":"2026-01-15 01:41","pubTimestamp":1768412497,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ad4729b76724ee1369972c52e1f4f65c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/26/01/49914952/crude-oil-gains-over-1-us-retail-sales-rise-0-6-in-november","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"economic,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QQQJ","TQQQ","QQQM","TSYW.SI","USJW.SI","QQQE","BK4134","BK4154","NVIW.SI","PSTV","QQQY",".IXIC","CLOV","GPIQ","QID","BCTX","MNQmain","PSQ","QYLG","BK4547","BK4185","IVPR","NQmain","QYLD","HUBC","IVP","QLD","USAW.SI","SQQQ","BK4139"],"gpt_icon":1},{"id":"2603648757","title":"Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges","url":"https://stock-news.laohu8.com/highlight/detail?id=2603648757","media":"Benzinga_recent_news","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603648757?lang=en_us&edition=fundamental","pubTime":"2026-01-15 00:36","pubTimestamp":1768408560,"startTime":"0","endTime":"0","summary":"Plus Therapeutics stock falls in premarket trading after pricing a $15 million public offering, with proceeds set for working capital as the company develops cancer treatments.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/14/Medical-Research-And-Development-Center-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/14/Medical-Research-And-Development-Center-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/penny-stocks/26/01/49912177/penny-cancer-stock-plus-therapeutics-raises-15-million-at-discount-stock-plunges","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/penny-stocks/26/01/49912177/penny-cancer-stock-plus-therapeutics-raises-15-million-at-discount-stock-plunges","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4532","IE00B2B36J28.USD","IE0009355771.USD","LU1814569148.SGD","LU1267930573.SGD","IE00BFXG1179.USD","LU1914381329.SGD","LU1854104046.USD","LU0053666078.USD","LU1323610961.USD","IE00B775H168.HKD","LU2491049909.HKD","LU2211815571.USD","LU0345770308.USD","LU0965509010.AUD","LU0912757837.SGD","LU1066051225.USD","LU1496350502.SGD","LU1718418525.SGD","BK4581","LU0689472784.USD","LU0203347892.USD","LU1854103824.USD","LU0976567544.SGD","LU0052756011.USD","LU1674673691.USD","LU0128525929.USD","BK4533","LU0094547139.USD","LU0048584097.USD","LU0310800379.SGD","LU0128525689.USD","LU1069347547.HKD","LU1119994496.HKD","LU1551013425.SGD","LU2244417387.USD","IE00B4JS1V06.HKD","LU2264538146.SGD","IE0004445239.USD","LU2361044865.SGD","SG9999002232.USD","IE00BFTCPJ56.SGD","LU1037948897.HKD","LU2271345857.HKD","LU2023251221.USD","LU1261432733.SGD","IE00B19Z9Z06.USD","IE0002270589.USD","LU0320765059.SGD","LU1267930730.SGD","SGXZ31699556.SGD","IE00B19Z3B42.SGD","LU0417517546.SGD","IE0005OL40V9.USD","LU0553294199.USD","IE00BWXC8680.SGD","LU0114720955.EUR","LU0211327993.USD","LU1934455194.USD","LU0795875169.SGD","LU0672654240.SGD","LU1791710400.SGD","LU2362541273.HKD","IE00BFSS7M15.SGD","SG9999013999.USD","LU1037948541.HKD","LU0079474960.USD","LU1153585028.USD","BK4217","LU0557290698.USD","LU2089284900.SGD","LU2112291526.USD","LU2552382215.SGD","LU0211326755.USD","LU0787776722.HKD","LU0310800965.SGD","IE00BJJMRZ35.SGD","LU2242649171.HKD","LU0187121727.USD","LU0256863811.USD","IE00BFSS8Q28.SGD","LU0861579265.USD","LU1061106388.HKD","LU1066051498.USD","LU0823416689.USD","LU0965508806.USD","LU0965509283.SGD","LU1066053197.SGD","LU1057294990.SGD","LU2357305700.SGD","PSTV","IE00B19Z3581.USD","SG9999014898.SGD","BK4154","LU2360032135.SGD","LU1988902786.USD","LU2362541513.USD","SG9999018865.SGD","LU2028103732.USD","LU2324357040.USD","LU0266013472.USD","BK4139","LU0354030511.USD","LU0965509101.SGD","LU0238689110.USD","LU1720051108.HKD","LU0353189680.USD","LU1732800096.USD","LU0738911758.USD","LU0882574055.USD","SG9999014880.SGD","IE00BKVL7J92.USD","LU0097036916.USD","SG9999014914.USD","LU2087625088.SGD","LU0354030438.USD","SGXZ99366536.SGD","LU1934455863.HKD","BK4534","LU2361045086.USD","IE00BZ1G4Q59.USD","LU0708994859.HKD","LU0353189763.USD","LU1506573853.SGD","IE00BZ9MQY76.HKD","LU0234572021.USD","SG9999014906.USD","LU1267930227.SGD","IE0004445015.USD","LU1066051811.HKD","LU1291159041.SGD","LU0949170772.SGD","LU0545039389.USD","LU1551013342.USD","LU2089984988.USD","IE00B19Z8W00.USD","LU0198837287.USD","LU1003077747.HKD","LU2347655156.SGD","SGXZ57979304.SGD","LU0795875086.SGD","IE00BN29S564.USD","LU1791710582.SGD","BK4007","IE00B894F039.SGD","LU0820562030.AUD","LU1670628061.USD","LU1983299246.USD","LU2491050071.SGD","LU1934455277.USD","LU0820561909.HKD","LU0011850046.USD","LU1074936037.SGD","LU0456855351.SGD","LU0820561818.USD","SG9999001176.USD","LU2468319806.SGD","SGXZ51526630.SGD","LU0432979614.USD","IE00B1XK9C88.USD","LU2236285917.USD","IE00BKPKM429.USD","LU0203345920.USD","LU1023059063.AUD","LU2552382058.USD","LU0528227936.USD","SG9999017495.SGD","LU1674673428.USD","IE00B19Z8X17.USD","IE00B1BXHZ80.USD","BK4588","IE00BSNM7G36.USD","BK4539","IE00BJJMRY28.SGD","LU0251132253.USD","IE00B7KXQ091.USD","LU1670627923.USD","LU2362540622.SGD","LU0109391861.USD","LU2552382132.HKD","SGXZ81514606.USD","LU0211328371.USD","LU0149725797.USD","LU1035773651.USD","LU1064131342.USD","IE00B4R5TH58.HKD","LU0345770993.USD","LU0342679015.USD","LU0107464264.USD","BK4585","SG9999001176.SGD","IE00B7SZLL34.SGD","LU1989771016.USD","LU1720051017.SGD","LU2461242641.AUD","LU0158827781.USD","LU0029864427.USD","LU0683600562.USD","LU2089283258.USD","LU0289739699.SGD","LU1778281490.HKD","BK4566","LU1084165304.USD","IE000M9KFDE8.USD","LU0058720904.USD","LU0158827948.USD","LU2491050154.USD","LU2133065610.SGD","LU0310799852.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","LU1267930490.SGD","LU2125154778.USD","LU0316494557.USD","LU0211326839.USD","LU0122379950.USD","LU0077335932.USD","LU0943347566.SGD","LU2125154935.USD","SG9999002224.SGD","SG9999018857.SGD","LU0496365809.HKD","IE00BJJMRX11.SGD","LU2111349929.HKD","IE00B19Z9P08.USD","LU0661504455.SGD","LU0708995401.HKD","IE00B19Z9505.USD","LU2279689827.SGD","LU2361044949.HKD","LU1732799900.SGD","LU1548497426.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://plustherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1076},{"period":"1month","weight":0.3569},{"period":"3month","weight":-0.4684},{"period":"6month","weight":-0.2888},{"period":"1year","weight":-0.5733},{"period":"ytd","weight":-0.367}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":-0.0089},{"period":"3month","weight":0.0086},{"period":"6month","weight":0.0686},{"period":"1year","weight":0.1594},{"period":"ytd","weight":0.0108}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.059718},{"month":2,"riseRate":0.541667,"avgChangeRate":0.036153},{"month":3,"riseRate":0.391304,"avgChangeRate":-0.044696},{"month":4,"riseRate":0.347826,"avgChangeRate":-0.02768},{"month":5,"riseRate":0.478261,"avgChangeRate":0.361181},{"month":6,"riseRate":0.25,"avgChangeRate":-0.076657},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.003883},{"month":8,"riseRate":0.291667,"avgChangeRate":-0.04175},{"month":9,"riseRate":0.541667,"avgChangeRate":-0.030103},{"month":10,"riseRate":0.291667,"avgChangeRate":-0.062759},{"month":11,"riseRate":0.375,"avgChangeRate":0.007725},{"month":12,"riseRate":0.375,"avgChangeRate":-0.028095}],"exchange":"NASDAQ","name":"Plus Therapeutics, Inc.","nameEN":"Plus Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Plus Therapeutics, Inc.(PSTV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Plus Therapeutics, Inc.(PSTV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Plus Therapeutics, Inc.,PSTV,Plus Therapeutics, Inc.股票,Plus Therapeutics, Inc.股票老虎,Plus Therapeutics, Inc.股票老虎国际,Plus Therapeutics, Inc.行情,Plus Therapeutics, Inc.股票行情,Plus Therapeutics, Inc.股价,Plus Therapeutics, Inc.股市,Plus Therapeutics, Inc.股票价格,Plus Therapeutics, Inc.股票交易,Plus Therapeutics, Inc.股票购买,Plus Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Plus Therapeutics, Inc.(PSTV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Plus Therapeutics, Inc.(PSTV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction